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Introduction: Understanding the mechanisms of drug resistance to
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
is essential to develop novel chemotherapies for non-small cell lung cancer
(NSCLC). Therefore, we analyzed the expression and function of ATP-
binding cassette (ABC) transporters in EGFR TKI-resistant NSCLC.
Methods: In three newly established AG1478-resistant NSCLC cell
lines, we evaluated the expression profile of ABC transporters and
genotyping of ABCG2 by real-time polymerase chain reaction and
elucidated their function by Hoechst dye efflux analyses. The
growth-inhibitory effect of the topoisomerase I inhibitor Hoechst
33342, which is extruded by ABCG2, was also investigated in these
cells using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphe-
nyl)-2-(4-sulfophenyl)-2H-tetrazolium assay.
Results: In AG1478-resistant cells, significantly less ABCG2 was
expressed, and the ratios of the cells with a strong ability to extrude
Hoechst dye were remarkably smaller than in the parent cells.
Because of the ABCG2 downregulation and loss of function due to
C421A/C421A homozygosity, PC-14AG50R was thus considered to
be more sensitive to Hoechst 33342 than the parental cells. All
AG1478-resistant cells were more sensitive to the combination of
Hoechst 33342 and AG1478 than to single agent.
Conclusions: Resistance to EGFR TKI in NSCLC is associated with
the downregulation of ABCG2 expression. A topoisomerase I inhibitor
alone or in combination with EGFR TKI might offer a promising
strategy for treating NSCLC that is resistant to EGFR TKI.
Key Words: Non-small cell lung cancer (NSCLC), Epidermal
growth factor receptor tyrosine kinase inhibitor (EGFR TKI), Drug
resistance, ABCG2, Topoisomerase I inhibitor.
(J Thorac Oncol. 2010;5: 1726–1733)
Non-small cell lung cancer (NSCLC) has become a majormalignancy in developed countries.1 Although patients
can be cured by surgery during the early stages, many
patients with residual tumors after surgery undergo chemo-
therapy. Various cytotoxic drugs including topoisomerase I
inhibitors are used against NSCLC.2 However, these tumors
are frequently resistant to such cytotoxic drugs, which sub-
sequently result in disease progression. Although previous
reports indicate that epidermal growth factor receptor ty-
rosine kinase inhibitors (EGFR TKIs), such as gefitinib and
erlotinib, are effective in a subpopulation of NSCLCs resis-
tant to conventional cytotoxic drugs, many tumors eventually
develop resistance even to these EGFR TKIs.3–9
Therefore, novel therapeutic strategies are essential for
patients with NSCLC resistance to EGFR TKIs.
One of the major mechanisms involved in drug resis-
tance is the presence of ATP-binding cassette (ABC) trans-
porter proteins on cancer cells. Among the various ABC
transporters, MDR1, ABCG2, and MRP1 are mainly associ-
ated with drug resistance.10–13 These molecules are expressed
on cell membranes and extrude various compounds including
chemotherapeutic drugs.13 NSCLCs frequently express high
levels of ABC transporters on their surface, which is consid-
ered to be associated with drug resistance in this type of
cancer.14,15 In fact, topoisomerase I inhibitors, such as irino-
tecan or Hoechst 33342, are known as substrates of ABCG2,
and their cytotoxic effect is suppressed in cells with high
ABCG2 expression levels.13 Gefitinib, one of the major
EGFR TKIs, is also known as a substrate of ABCG2.16,17
Hence, expression of ABC transporters could be one of the
major factors associated with resistant to EGFR TKIs.
Several other molecules are also involved in resistance
to EGFR TKIs in lung cancer.7–9 The EGFRmutation T790M
is one of the major mechanisms associated with resistance to
EGFR TKIs and is occasionally identified in these EGFR
TKIs-resistant tumors. It is thought to cause a conformational
change of the tyrosine kinase domain of EGFR and blocks the
binding of TKIs to EGFR, which confers resistance to EGFR
TKIs. Amplification of the MET gene is also found in tumors
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resistant to EGFR TKIs and is involved in the resistance
through undetermined mechanisms. These results suggest
that resistance to EGFR TKIs involves complicated genetic
events.
In this study, several NSCLC cell lines were estab-
lished that were resistant to an EGFR TKI. Taking advantage
of these cell lines, the functions of various ABC transporter
genes and genetic changes of EGFR gene were analyzed to
explore the involvement of these molecules in the resistance
to the EGFR TKI. The results of this study showed that
ABCG2 is downregulated in these EGFR TKI-resistant cell
lines, which suggested that other chemotherapeutic agents
extruded by ABCG2 could overcome resistance to EGFR
TKIs in NSCLC. To test this possibility, the growth-inhibi-
tory effect of a topoisomerase I inhibitor, alone or in combi-
nation with an EGFR TKI, were examined to determine
whether this strategy could actually overcome resistance to
EGFR TKIs.
MATERIALS AND METHODS
Lung Adenocarcinoma Cell Lines
The lung adenocarcinoma cell lines 11-18 and A549
harboring an L858R mutation and the wild-type EGFR gene
were obtained from the Cell Resource Center for Biomedical
Research, Tohoku University (Sendai, Japan), respectively.18
PC-14, which harbors a delE746-A750 mutation of EGFR,
was purchased from the Riken Bioresource Center (Tsukuba,
Japan).18 NCI-H1650 and NCI-H1975 harboring delE746-
A750 and L858R plus T790M mutations were purchased
from The American Type Culture Collection (Manassas,
VA), respectively.19 All cell lines were maintained in RPMI
1640 (Invitrogen, Grand Island, NY) supplemented with 10%
fetal bovine serum (FCS; Invitrogen) and 1% penicillin/
streptomycin (Invitrogen).
Establishment of EGFR TKI-Resistant Cell Lines
EGFR TKI-resistant cell lines were established using
AG1478, a biologic analogue of the major TKIs, gefitinib and
erlotinib. Five parental cell lines were cultured in the pres-
ence of 10 M of AG1478 (BIOMOL, Plymouth Meeting,
PA), and the concentration was increased stepwise until
growth was satisfactorily inhibited. Small fractions of cells
that survived at certain concentration of AG1478 were con-
tinuously maintained under the same AG1478 concentration
until they finally showed a stable proliferation.
Growth Inhibition Assay
Growth inhibition was colorimetrically assessed using the
Cell Titer 96 Aqueous One Solution Cell Proliferation Assay
(Promega, Madison, WI) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium in-
ner salt according to the manufacturer’s instructions.
Direct Sequencing of EGFR
Exons 18 to 21 of EGFR were directly sequenced using
genomic DNA in these cell lines as described to detect EGFR
mutations.19–21
Real-Time Polymerase Chain Reaction
The messenger RNA expression levels for ABCG2,
MDR1, MRP1, EGFR, and RNase P genes were verified
using TaqMan gene expression assays (Applied Biosystems,
Foster City, CA) and a 7500 Real-Time Polymerase Chain
Reaction System (Applied Biosystems) as recommended by
the manufacturer, normalized to RNase P of the housekeep-
ing gene. Each experiment was run in triplicate.
Genotyping of ABCG2
The single-nucleotide polymorphism (SNP) of ABCG2
gene has been reported to influence the function of ABCG2
transporter.17,22 The genotyping of ABCG2 (C421C/C, C/A,
and A/A) was thus examined using TaqMan genotyping
assays (Applied Biosystems, Foster City, CA) and a 7500
Real-Time Polymerase Chain Reaction System (Applied Bio-
systems), as recommended by the manufacturer.
Hoechst Dye Efflux Analysis
Hoechst dye efflux analyses, referred to as side popu-
lation (SP) analyses originally established to detect cancer
stem cells, can isolate cells with strong ability to extrude
Hoechst dye. The isolated SP cells with low blue-red profile
are assumed to have enhanced activity of ABC transporter
proteins that are associated with efflux of Hoechst dye.23,24
Therefore, Hoechst dye efflux analyses of NSCLC cell lines
were herein performed to evaluate the functions of ABC
transporter proteins as described previously with modifica-
tion.25 SP cells are characteristics of being diminished in the
presence of blockers of Hoechst 33342-transporter activity,
such as verapamil or reserpine.26,27 Because of an insufficient
blocking effect by verapamil in the cells lines analyzed
herein, we used 10 M of AG1478 to block Hoechst dye
transporters, which, therefore, remarkably decreased the frac-
tion in the SP gate of all cell lines.
Statistical Analysis
The significance of differences was tested using two-
tailed Student’s t test for paired data. All statistical calcula-
tions were performed using SPSS version 11.0 software for
Windows (SPSS, Chicago, IL). All statistical tests were two
sided, and differences were judged statistically significant at
values of p  0.05.
RESULTS
Establishment of AG1478-Resistant Cell Lines
Three AG1478-resistant sublines PC-14AG50R, NCI-
H1650AG20R, and 11-18AG10R were successfully estab-
lished as described later.
Very small fractions of PC-14, NCI-H1650, and 11-18
cells that survived in culture supplemented with 50, 20, and
10 M AG1478 were isolated, respectively. After culturing
for 40 to 65 days, all these cells acquired the ability to grow
continuously in the presence of AG1478 at the respective
concentrations. These AG1478-resistant sublines are referred
to as PC-14AG50R, NCI-1650AG20R, and 11-18AG10R,
respectively. Although NCI-H1650 and 11-18 were sensitive
to AG1478 with concentration that inhibits 50% (IC50) values
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of 1 M, their derivative sublines NCI-H1650AG20R and
11-18AG10R were resistant to AG1478 with IC50 values of
10 M (Figures 1A, B). Although PC-14 was relatively
resistant to AG1478 with an IC50 of 1 M, PC-14AG50R
showed resistance up to 100 M of AG1478 (Figure 1C).
Growth of NCI-H1975 and A549 cells were not inhibited
even at 50 M of AG1478, thus suggesting that they were
already resistant to this drug. These established cell lines
were stably resistant to AG1478 even after 1 month under
culture in the AG1478-free medium (data not shown), which
proved the stable resistance to AG1478 of these lines.
EGFR Mutations in NSCLC Cell Lines
Direct sequencing showed that the cell lines PC-14,
NCI-H1650, NCI-H1975, and 11-18 harbored the known
EGFR mutations and that A549 harbored wild-type EGFR
(data not shown). The drug-resistant cell lines PC-14AG50R,
NCI-H1650AG20R, and 11-18AG10R had the identical
EGFR mutations to their parental cell lines. The T790M
mutation was undetectable in all AG1478-resistant cell lines.
Expression of ABCG2, MDR1, MRP1, and EGFR
in Cell Lines
Significantly less ABCG2 was expressed in the 3
AG1478-resistant cell lines than in their parental cell lines
(Figure 2A). All cell lines except A549 expressed very low
levels of MDR1, and parental and resistant cell lines did not
apparently differ in this respect (Figure 2B). In comparison
with their respective parental cell lines, less MRP1 was
expressed in PC-14AG50R and NCI-H1650AG20R but was
expressed at a higher level in 11-18AG10R (Figure 2C). The
profile of EGFR expression was similar to that of MRP1
expression (Figure 2D).
Hoechst Dye Efflux Analyses
The Hoechst blue-red profiles of the original five
NSCLC cell lines indicated a distinct fraction in SP gate
(3.54–22.0%; Figure 3A). The AG1478-resistant cell lines
PC-14AG50R, NCI-H1650AG20R, and 11-18AG10R con-
tained remarkably smaller SP cells than their parental lines.
In comparison with PC-14AG50R and NCI-H1650AG20R,
this fraction in 11-18AG10R did not completely disappear
(Figure 3B). To exclude the possibility that residual AG1478
added during culture interfered with Hoechst 33342 efflux in
the SP analysis of AG1478-resistant cell lines, A549 and
NCI-H1975 were cultured for 1 week with 10 M AG1478
followed by an SP analysis. Both cell lines contained ratios of
SP cells that were similar to the same lines cultured without
AG1478, thus suggesting that residual AG1478 did not ham-
per the efflux of Hoechst 33342 (data not shown).
Genotyping of ABCG2
The genotyping of ABCG2 revealed C421A/C421A
homozygous SNP in both PC-14 and PC-14AG50R cell lines.
In contrast, NCI-H1650AG20R and 11-18AG10R, as well as
their parental lines, showed the wild genotype of ABCG2
(Table 1).
FIGURE 1. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assay of non-small cell lung
cancer (NSCLC) cell lines. Mean  standard error
of the mean (SEM); n  3. A, NCI-H1650 and
NCI-H1650AG20R. B, 11-18 and 11-18AG10R.
Although NCI-H1650 and 11-18 were sensitive to
AG1478 with concentration that inhibits 50%
(IC50) values of 1 M, their derivative sublines,
NCI-H1650AG20R and 11-18AG10R, were resis-
tant to AG1478 with IC50 values of 10 M.
C, PC-14 and PC-14AG50R. Although PC-14 cells
were relatively resistant to AG1478 with an IC50
value of 1 M, PC-14AG50R was more resistant
than PC-14 to concentrations of AG1478 up to
100 M.
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Growth-Inhibitory Effect of Hoechst 33342 in
Cell Lines
Hoechst 33342 has DNA-binding properties and be-
longs to the topoisomerase I inhibitor class of anticancer
drugs.28 Hoechst 33342 is extruded from cells mainly by
ABCG2, which suggests that the growth-inhibitory effect of
Hoechst 33342 would be enhanced in AG1478-resistant cell
lines with downregulated ABCG2 expression in comparison
with cell lines with normal ABCG2 expression.13 Therefore,
the cytotoxic effect of various concentrations of Hoechst
33342 in the presence or absence of AG1478 was analyzed to
determine whether this agent could be effective in lung
cancer cell lines resistant to AG1478.
The growth-inhibitory effect of 1 g/ml Hoechst 33342
alone against PC-14 was limited (relative growth to PC-14
without Hoechst 33342: 47%  6.5%). In contrast, the
growth of PC-14AG50R was remarkably inhibited by the
same concentration of Hoechst 33342 (relative growth to
PC-14AG50R without Hoechst 33342: 3.8%  0.5%, p 
0.001 versus PC-14; Figure 4A). The effect of Hoechst 33342
against NCI-H1650AG20R or 11-18AG10R did not remark-
ably differ from that in their respective parental lines (data
not shown).
The combination of 1 M of AG1478 and 0.1 g/ml of
Hoechst 33342 demonstrated cytotoxicity in PC-14AG50R,
which was resistant to either one of these drugs at the
respective concentrations (Figure 4B). Another AG1478-re-
sistant cell line, NCI-H1650AG20R, was also sensitive to the
combination of 1 M of AG1478 and 0.1 g/ml of Hoechst
33342, although it was resistant to either one of these drugs
at the respective concentrations (Figure 4B). Furthermore, the
combination therapy for 1 M of AG1478 and 1 g/ml of
Hoechst 33342 was more effective to three AG1478-resistant
cell lines, compared with the monotherapy of 1 g/ml of
Hoechst 33342 (Figure 4C).
DISCUSSION
In this study, novel NSCLC cell lines were established
that were resistant to the gefitinib and erlotinib analogue
AG1478, and their biologic and molecular features were
FIGURE 2. Messenger RNA (mRNA) expression of ATP-binding cassette (ABC) transporter genes and EGFR in non-small cell
lung cancer (NSCLC) cell lines. A, ABCG2. B, MDR1. C, MRP1. D, EGFR. The relative amount of mRNA of each gene to that of
RNase P gene is shown as a normalized value of expression. Significantly less ABCG2 was expressed in AG1478-resistant cell
lines than in the parental cell lines. PC14AG50R: 0.22  0.02 versus PC14: 1.54  0.09 (p  0.001); NCI-H1650A20R:
0.07  0.006 versus NCI-H1650: 0.46  0.01 (p  0.001); and 11-18AG10R: 1.09  0.03 versus 11-18: 1.60  0.05 (p 
0.001) (A). Very little MDR1 was expressed in all cell lines except A549 (B). Less MRP1 and EGFR were expressed in PC-
14AG50R and NCI-H1650AG20R, but more were expressed in 11-18AG10R than in the respective parental cell lines (C, D).
Mean  SEM; n  3.
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investigated with focus on three ABC transporters and
EGFR. Although several EGFR TKI-resistant lung cancer
cell lines have already been established, the mechanisms
underlying resistance involving ABC transporters have yet
to be determined.9,29
Notably, ABCG2 expression was significantly sup-
pressed, and the proportion of the cells in SP gate in all
AG1478-resistant cell lines was smaller than that in their
parental lines, thus reflecting decreased ability to extrude
TABLE 1. Genotype of EGFR and ABCG2 of NSCLC Cell Lines
Cell Lines EGFR Mutation ABCG2 SNP
PC-14/PC-14AG50R Del E746-A750 C421A/C421A
NCI-H1650/NCI-H1650AG20R Del E746-A750 Wild type
11–18/11–18AG10R L858R Wild type
EGFR, epidermal growth factor receptor; ABC, ATP-binding cassette; NSCLC,
non-small cell lung cancer; SNP, single-nucleotide polymorphism.
FIGURE 3. Hoechst-dye efflux analyses of non-small cell lung cancer (NSCLC) cell lines. A, NCI-H1975: This cell line
contained a distinct fraction in side population (SP) gate. The numbers on the graphs indicate the ratio (%) of each
gated cell fraction. The fraction in SP gate significantly decreased after adding AG1478. B. Drug-resistant cell lines com-
pared with their parental cells. AG1478-resistant cell lines PC-14AG50R, NCI-H1650AG20R, and 11-18AG10R had re-
markably diminished fractions in SP gate, in comparison with the respective parental lines. PC-14AG50R versus PC-14:
0%  0.016% versus 2.73%  2.25% (p  0.025); NCI-H1650AG20R versus NCI-H1650: 0% versus 5.05  6.75%; and
11-18AG10R versus 11-18: 1.04%  0.73% versus 14.5%  8.2% (p  0.036). Mean  SEM; n  4 (n  1 for
NCI-H1650AG20R).
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Hoechst 33342 through downregulated ABCG2 expression.
Very little MDR1 gene was expressed in the resistant cell
lines and in their parental lines, thus suggesting that MDR1 is
minimally involved in AG1478 resistance. Furthermore, the
MRP1 and EGFR expression levels in AG1478-resistant cell
lines varied in comparison with their parental lines. The
T790M mutation was not detected in any of the three resistant
cell lines. Although minor clone with the T790M mutation
which cannot be detected by direct sequencing might exist in
these cell lines, such minor cell population is not considered
to be the major cause of AG1478 resistance, because most of
the cells were still viable when treated by 1 M of AG1478
(Figure 1). These results suggest that alterations in ABCG2
expression are closely associated with AG1478 resistance in
these cell lines. Why ABCG2 expression was diminished in
the AG1478-resistant cell lines remains unknown. ABCG2
expression was significantly elevated in a Hoechst-33342-
resistant cell line, in comparison with its parental cell line
(data not shown). Therefore, the ABCG2 expression profiles
differed between the cell lines resistant to AG1478 and
Hoechst 33342, although both drugs are substrates of
ABCG2.16,17 This discrepancy may be partly explained by
the fact that EGFR TKI works as an inhibitor of ABCG2 at
high concentrations (1 M), although EGFR TKI is a
substrate of ABCG2 at low concentrations (1 M).16,17,30
All our EGFR TKI-resistant cells were selected in high
concentrations of EGFR TKI (10 M). Such high con-
centrations of EGFR TKI may, therefore, have reduced the
proliferative benefits of the cells with a strong ABCG2
expression. Another explanation is that AG1478 might
also regulate the ABCG2 expression or localization
through some unknown mechanisms. In fact, gefitinib
FIGURE 4. 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays of cell
lines resistant to AG1478 and Hoechst 33342. A, Hoechst 33342 (1 g/ml) slightly inhibited growth of PC-14 but remarkably
inhibited that of PC14AG50R. B, Left: Addition of 1 M AG1478 further enhanced the cytotoxic effect of Hoechst 33342.
Mean  SEM; n  4. Right: AG1478 (1 M) did not inhibit growth of NCI-H1650AG20R alone but adding Hoechst
33342 dose dependently restored the effect of AG1478; n  3. C, The combination therapy for AG1478 (1 M) and
Hoechst 33342 (1 g/ml) was more effective to these three AG1478-resistant cell lines, when compared with Hoechst
33342 (1 g/ml) monotherapy; n  3.
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causes ABCG2 translocation from the cellular membrane
to the perinuclear region.31
This study provided evidence that the cells in SP gate
are involved in drug resistance, because the number of these
cells was reduced in concordance with the level of ABCG2
expression in AG1478-resistant cell lines. In contrast, the
cells in SP gate of the Hoechst-33342-resistant cell line with
an enhanced ABCG2 expression increased in comparison
with the parental line (data not shown). Furthermore, the
addition of AG1478 in the SP analysis significantly reduced
the number of the fraction in the SP gate, possibly due to
ABCG2 inhibition (Figure 3). Taken together, the fraction in
the SP gate in the NSCLC cell lines seems to be largely
dependent on the functions of ABC transporters, particularly
those of ABCG2.
On the basis of the results that ABCG2 is downregu-
lated and the number of the fraction of SP gate is decreased
in AG1478-resistant cell lines, we hypothesized that other
chemotherapeutic agents that are extruded by ABCG2 could
be effective against resistance to AG1478. To test this pos-
sibility, Hoechst 33342 was chosen as a cytotoxic drug
because its mechanism of action is similar to that of irinote-
can, a topoisomerase I inhibitor widely used in NSCLCs.
Most strikingly, AG1478-resistant PC-14AG50R with sup-
pressed ABCG2 expression was more sensitive than its pa-
rental line PC-14 to 1 g/ml Hoechst 33342 alone. It is very
likely that the downregulation of ABCG2 in PC-14AG50R
enhanced the sensitivity to Hoechst 33342 in comparison
with its parental cell line. This result suggests that cytotoxic
drugs that are substrates of ABCG2 might be more effective
in EGFR TKI-resistant tumor cells with suppressed ABCG2
expression than in the original cells, at least in a subset of
NSCLCs. Patients with lung cancers who have acquired
resistance to gefitinib sometimes regain sensitivity to other
cytotoxic drugs.32 The present results might provide the
molecular basis for this paradox. Unlike PC-14AG50R, the
cytotoxicity of Hoechst 33342 against NCI-H1650AG20R
and 11-18AG10R cell lines was not enhanced in comparison
with their parental lines. Therefore, mechanisms other than
ABCG2 expression might contribute to the sensitivity to
Hoechst 33342 in these cell lines. Because SNP C421CA of
ABCG2 is related to the loss of the ABCG2 functions,
C421A/C421A homozygosity in PC-14 and PC-14AG50R
may, therefore, result in a reduced ability to extrude Hoechst
33342.17,22 This genotype, together with a low expression of
ABCG2, may, therefore, have synergistically enhanced the
activity of Hoechst 33342, in contrast to NCI-H1650AG20R
and 11-18AG10R with a normal genotype.
An investigation of the combination of Hoechst 33342
and AG1478 revealed three AG1478-resistant cell lines to be
sensitive to 1 M of AG1478 when cultured with 0.1 or 1
g/ml of Hoechst 33342, although each drug alone was not
effective at their respective concentrations. Gefitinib is
known to suppress the ATPase activity of ABCG2 and inhibit
drug extrusion at high concentrations (1 M).17,30 There-
fore, it is likely that AG1478 further suppressed the function
of ABCG2 to extrude Hoechst 33342 and thus exerted an
enhanced cytotoxicity in all these cell lines. It is yet to be
determined whether low expression of ABCG2 or suppres-
sion of ABCG2 by an EGFR TKI mainly contributed to this
growth-inhibitory effect. One micrometer of AG1478 is
equivalent to 1 M of gefitinib, and administering 1 M
gefitinib is considered tolerable by patients with NSCLC,
because the therapeutic plasma level of gefitinib is approxi-
mately 2 M.33 Therefore, EGFR TKI might be still effec-
tive against tumors resistant to EGFR TKI when administered
together with topoisomerase I inhibitors and therapy with an
EGFR TKI combined with a topoisomerase I inhibitor is
considered feasible for treating NSCLCs resistant to EGFR
TKI. As a major limitation, we adopted only Hoechst 33342
as an antitumor agent extruded by ABCG2 in this study.
Further studies will be necessary to elucidate whether other
types of drugs pumped off by ABCG2 is also effective in
these TKI-resistant cell lines.
In conclusion, resistance to AG1478 in NSCLCs is
associated with ABCG2 downregulation. A topoisomerase I
inhibitor alone or in combination with EGFR TKI might,
therefore, be a promising treatment modality for a subset of
EGFR TKI-resistant NSCLC.
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